ClinTec International, a global CRO with a substantial presence in the Middle East and Africa has expanded its operations into Malawi. A top 5 pharmaceutical company with sales exceeding US$50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East. The global vaccines market has an estimated value of US$33.8 billion.
Africa is a pivotal region for the development of adult and pediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programs. The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.
Vaccine development faces its own challenges associated with local immunization recommendations as well as stringent cold chain management. ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, while complying in full with international clinical research guidelines.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.